Roivant, Pharvaris and others rise on Tuesday gains
Roivant Sciences jumped after topline Phase 2 PHocus data for mosliciguat in pulmonary hypertension associated with interstitial lung disease. Pharvaris also climbed on topline Phase 3 CHAPTER-3 results, while Eos Energy, IonQ, Factorial Energy, Bloom Energy, Applied Optoelectronics and Aehr Test Systems also gained.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.